Symbicort is a prescription drug used to treat asthma and chronic obstructive pulmonary disease (COPD). Learn how to lower long-term costs and more.

The first Symbicort generic, simply referred to as budesonide/formoterol inhaler, was approved by the Food and Drug Administration (FDA) in February 2020 and is roughly half the cost of Symbicort.

Viatris (formerly Mylan) has become the first drugmaker to win full FDA approval for a generic version of AstraZeneca's top-selling respiratory drug Symbicort, although launch plans remain ...

Viatris announced the launch of Breyna ™ (budesonide and formoterol fumarate dihydrate) inhalation aerosol, the first generic version of AstraZeneca’s Symbicort ®.. Breyna is a metered-dose ...

In Symbicort, this drug is formoterol, and in Advair it’s salmeterol. Symbicort comes in a metered dose inhaler. Advair, on the other hand, comes in two forms: Advair HFA and Advair Diskus.

This extended the lapse date of a key patent for Symbicort to July 2023. But with just six months until that patent expires, Viatris could soon launch its generic version of Symbicort, known as ...

An AstraZeneca report said Symbicort sales earned the company more than $2.7 billion last year. The U.S. Food and Drug Administration tentatively approved Viatris' Breyna, the first generic ...

The first generic version of Symbicort -- a metered-dose inhaler that combines the corticosteroid budesonide with the long-acting bronchodilator formoterol -- has been approved for asthma and ...

Viatris Inc.VTRS announced that the company and partner Kindeva Drug Delivery L.P. have won a court decision that invalidates AstraZeneca's AZN patent for Symbicort.. The U.S. District Court for ...

Those device patents extended patent exclusivity for more than six years, helping Symbicort become AstraZeneca’s second-highest-selling drug in any category in 2021, generating more than $2.7 ...